为了打破这些认知局限，来自郑州大学人民医院神经内科以及郑州大学医学科学院的研究人员，开展了一项意义重大的研究。他们将目光聚焦于一个中国汉族三代家庭，试图从这个家庭的遗传密码中找到解开 FTD 谜团的线索。

AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...

AVB-101 is designed to halt disease progression by delivering a functional progranulin (GRN) gene. It was administered to a patient with frontotemporal dementia (FTD) carrying GRN gene mutations ...

Passage Bio, Inc. announced interim results from its PBFT02 clinical trial for frontotemporal dementia (FTD) patients with the GRN mutation, revealing significant increases in cerebrospinal fluid ...

Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history ...

“We are pleased to report strong performance in 2024 as we meaningfully advanced our PBFT02 program, delivering promising data in FTD-GRN patients showing robust, durable progranulin expression ...

Interim clinical data from the Phase 1/2 upliFT-D study in FTD-GRN participants showed that gene replacement by ICM administration of PBFT02 resulted in robust PGRN elevations in the CSF.